Bristol Myers Squibb (CELG-RI) Gross Margin Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Gross Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Gross Margin Growth (1y) (Qtr) |
| 1 |
Gsk |
93,699,046.73 Bn |
93,699,041.77 Bn |
7.76 Bn |
119.00 |
| 2 |
Eli Lilly |
1,012.06 Bn |
1,006.77 Bn |
16.22 Bn |
-59.00 |
| 3 |
Johnson & Johnson |
560.67 Bn |
538.62 Bn |
15.96 Bn |
-8.00 |
| 4 |
AbbVie |
402.20 Bn |
392.85 Bn |
10.78 Bn |
188.00 |
| 5 |
Merck |
298.59 Bn |
292.94 Bn |
12.09 Bn |
-374.00 |
| 6 |
Amgen |
188.77 Bn |
176.74 Bn |
5.87 Bn |
458.00 |
| 7 |
Gilead Sciences |
160.22 Bn |
152.49 Bn |
5.52 Bn |
234.00 |
| 8 |
Pfizer |
148.19 Bn |
135.42 Bn |
-1.21 Bn |
-1,705.00 |
| 9 |
Bristol Myers Squibb |
116.72 Bn |
106.26 Bn |
8.07 Bn |
-270.00 |
| 10 |
Bristol Myers Squibb |
- |
- |
8.07 Bn |
-270.00 |
| Date | Value |
|---|
| Mar 31, 2026 |
-270.00 |
| Dec 31, 2025 |
622.00 |
| Sep 30, 2025 |
-324.00 |
| Jun 30, 2025 |
-71.00 |
| Mar 31, 2025 |
-237.00 |
| Dec 31, 2024 |
-1,507.00 |
| Sep 30, 2024 |
-201.00 |
| Jun 30, 2024 |
-116.00 |
| Mar 31, 2024 |
-208.00 |
| Dec 31, 2023 |
-118.00 |
| Sep 30, 2023 |
-188.00 |
| Jun 30, 2023 |
-274.00 |
| Mar 31, 2023 |
-142.00 |
| Dec 31, 2022 |
-308.00 |
| Sep 30, 2022 |
-127.00 |
| Jun 30, 2022 |
-193.00 |
| Mar 31, 2022 |
444.00 |
| Dec 31, 2021 |
663.00 |
| Sep 30, 2021 |
403.00 |
| Jun 30, 2021 |
569.00 |
